Center-Authored Papers

Filters: Author is Ho, Vincent T  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ.  2008.  Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(2):197-207. Abstract
D
Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Ritz J, Sorror ML, Lee SJ, Deeg HJ et al..  2012.  A disease risk index for patients undergoing allogeneic stem cell transplantation.. Blood. 120(4):905-13. Abstract
F
Williams KM, Cheng G-S, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S et al..  2016.  Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(4):710-716. Abstract
I
Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M et al..  2015.  Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(2):266-74. Abstract
Martin PS, Li S, Nikiforow S, Alyea EP, Antin JH, Armand P, Cutler CS, Ho VT, Kekre N, Koreth J et al..  2016.  Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.. Haematologica. 101(4):499-505. Abstract
L
Cheng G-S, Storer B, Chien JW, Jagasia M, Hubbard JJ, Burns L, Ho VT, Pidala J, Palmer J, Johnston L et al..  2016.  Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation.. Annals of the American Thoracic Society. Abstract
P
Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ et al..  2014.  Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.. Blood. 124(22):3221-7;quiz3335. Abstract
Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C et al..  2012.  Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
Bredeson C, Le Rademacher J, Kato K, Dipersio JF, Agura E, Devine SM, Appelbaum FR, Tomblyn MR, Laport GG, Zhu X et al..  2013.  Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.. Blood. Abstract
Sorror ML, Logan BR, Zhu X, Rizzo DJ, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC.  2015.  Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A CIBMTR(®) Study.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
R
Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, Difronzo NL et al..  2014.  A Randomized Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia Syndrome Following Allogeneic Stem Cell Transplantation.A Blood and Marrow Transplant Clinical Tri. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Abstract
Macmillan ML, Robin M, Harris AC, Defor TE, Martin PJ, Alousi A, Ho VT, Bolaños-Meade J, Ferrara JLM, Jones R et al..  2015.  A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(4):761-7. Abstract
S
Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong C-H, Wang H, Chin A et al..  2013.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.. The New England journal of medicine. 369(6):529-39. Abstract